Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

Essie Samuel; Jiehyun Lee

Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

Department of Pharmacy Practice

Research output: Contribution to journal › Article › peer-review

Abstract

The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney’s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.

Original language	American English
Journal	U.S. Pharmacist
Volume	42
State	Published - Oct 13 2017

Disciplines

Medicine and Health Sciences

Cite this

@article{804b6b3527744fe482a347d4b3654332,

title = "Sodium-Glucose Cotransporter 2 Inhibitors: An Overview",

abstract = " The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney{\textquoteright}s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.",

author = "Essie Samuel and Jiehyun Lee",

year = "2017",

month = oct,

day = "13",

language = "American English",

volume = "42",

journal = "U.S. Pharmacist",

}

TY - JOUR

T1 - Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

AU - Samuel, Essie

AU - Lee, Jiehyun

PY - 2017/10/13

Y1 - 2017/10/13

N2 - The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney’s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.

AB - The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney’s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.

UR - https://digitalcommons.pcom.edu/scholarly_papers/1888

M3 - Article

VL - 42

JO - U.S. Pharmacist

JF - U.S. Pharmacist

ER -

Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

Abstract

Disciplines

Other files and links

Cite this